Wedbush Initiates Coverage On Immunome with Outperform Rating, Announces Price Target of $12
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has initiated coverage on Immunome (NASDAQ:IMNM) with an Outperform rating and set a price target of $12.

December 19, 2023 | 12:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst David Nierengarten initiated coverage on Immunome with an Outperform rating and a price target of $12.
Analyst ratings, especially from reputable firms like Wedbush, can significantly influence investor sentiment and stock prices. An Outperform rating suggests that the analyst believes IMNM will perform better than the market or its sector, which could lead to increased investor interest and a potential rise in the stock price in the short term. The announcement of a price target of $12, which is presumably higher than the current trading price, further underscores the analyst's bullish stance on the stock.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100